JP2014098050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014098050A5 JP2014098050A5 JP2014040227A JP2014040227A JP2014098050A5 JP 2014098050 A5 JP2014098050 A5 JP 2014098050A5 JP 2014040227 A JP2014040227 A JP 2014040227A JP 2014040227 A JP2014040227 A JP 2014040227A JP 2014098050 A5 JP2014098050 A5 JP 2014098050A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- daily dose
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 45
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940074046 glyceryl laurate Drugs 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 5
- 238000005481 NMR spectroscopy Methods 0.000 claims 5
- 239000000654 additive Substances 0.000 claims 5
- -1 glycerol ester Chemical class 0.000 claims 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 230000000996 additive effect Effects 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 239000012535 impurity Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000019439 ethyl acetate Nutrition 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- DPHUWDIXHNQOSY-UHFFFAOYSA-N napabucasin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1OC(C(=O)C)=C2 DPHUWDIXHNQOSY-UHFFFAOYSA-N 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 239000013557 residual solvent Substances 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31588610P | 2010-03-19 | 2010-03-19 | |
| US31589010P | 2010-03-19 | 2010-03-19 | |
| US61/315,890 | 2010-03-19 | ||
| US61/315,886 | 2010-03-19 | ||
| US32581410P | 2010-04-19 | 2010-04-19 | |
| US61/325,814 | 2010-04-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500246A Division JP5602935B2 (ja) | 2010-03-19 | 2011-03-21 | がん幹細胞を標的とするための新規の化合物および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016194176A Division JP2016222723A (ja) | 2010-03-19 | 2016-09-30 | がん幹細胞を標的とするための新規の化合物および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014098050A JP2014098050A (ja) | 2014-05-29 |
| JP2014098050A5 true JP2014098050A5 (enExample) | 2014-12-11 |
Family
ID=50940329
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014040225A Expired - Fee Related JP5993390B2 (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2014040227A Withdrawn JP2014098050A (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2014040226A Withdrawn JP2014098049A (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2015035285A Pending JP2015098489A (ja) | 2010-03-19 | 2015-02-25 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2015179115A Expired - Fee Related JP6246169B2 (ja) | 2010-03-19 | 2015-09-11 | がん幹細胞を標的とするための新規の方法 |
| JP2016194176A Withdrawn JP2016222723A (ja) | 2010-03-19 | 2016-09-30 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2017199380A Withdrawn JP2018002744A (ja) | 2010-03-19 | 2017-10-13 | がん幹細胞を標的とするための新規の方法 |
| JP2018081329A Withdrawn JP2018115209A (ja) | 2010-03-19 | 2018-04-20 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2020014705A Withdrawn JP2020063308A (ja) | 2010-03-19 | 2020-01-31 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2020082479A Pending JP2020114888A (ja) | 2010-03-19 | 2020-05-08 | がん幹細胞を標的とするための新規の方法 |
| JP2021197732A Pending JP2022020002A (ja) | 2010-03-19 | 2021-12-06 | がん幹細胞を標的とするための新規の化合物および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014040225A Expired - Fee Related JP5993390B2 (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014040226A Withdrawn JP2014098049A (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2015035285A Pending JP2015098489A (ja) | 2010-03-19 | 2015-02-25 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2015179115A Expired - Fee Related JP6246169B2 (ja) | 2010-03-19 | 2015-09-11 | がん幹細胞を標的とするための新規の方法 |
| JP2016194176A Withdrawn JP2016222723A (ja) | 2010-03-19 | 2016-09-30 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2017199380A Withdrawn JP2018002744A (ja) | 2010-03-19 | 2017-10-13 | がん幹細胞を標的とするための新規の方法 |
| JP2018081329A Withdrawn JP2018115209A (ja) | 2010-03-19 | 2018-04-20 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2020014705A Withdrawn JP2020063308A (ja) | 2010-03-19 | 2020-01-31 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2020082479A Pending JP2020114888A (ja) | 2010-03-19 | 2020-05-08 | がん幹細胞を標的とするための新規の方法 |
| JP2021197732A Pending JP2022020002A (ja) | 2010-03-19 | 2021-12-06 | がん幹細胞を標的とするための新規の化合物および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP3295796A1 (enExample) |
| JP (11) | JP5993390B2 (enExample) |
| CN (3) | CN104016951B (enExample) |
| CA (3) | CA2993363A1 (enExample) |
| DK (1) | DK3108750T3 (enExample) |
| ES (1) | ES2689928T3 (enExample) |
| HU (1) | HUE066482T2 (enExample) |
| NZ (2) | NZ701237A (enExample) |
| PT (1) | PT2547205T (enExample) |
| RU (2) | RU2657750C1 (enExample) |
| SG (3) | SG10201502079VA (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| CN104016951B (zh) * | 2010-03-19 | 2016-07-13 | 北京强新生物科技有限公司 | 靶向癌症干细胞的化合物和组合物 |
| DK2547205T3 (da) * | 2010-03-19 | 2024-05-27 | 1Globe Biomedical Co Ltd | Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller |
| US20160030384A1 (en) | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
| WO2016196935A1 (en) * | 2015-06-03 | 2016-12-08 | Boston Biomedical, Inc. | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| JP6751658B2 (ja) | 2016-11-15 | 2020-09-09 | クラリオン株式会社 | 音声認識装置、音声認識システム |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| KR20240012436A (ko) * | 2021-05-25 | 2024-01-29 | 액티브 바이오테크 에이비 | 복수의 타스퀴니모드 입자 및 그 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61205257A (ja) * | 1985-03-08 | 1986-09-11 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤 |
| EP0945131A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Perorale Wirkstoff-Suspension |
| JP2003525862A (ja) * | 1999-01-27 | 2003-09-02 | ザ ユニヴァーシティー オブ サウス フロリダ | ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害 |
| WO2004026253A2 (en) * | 2002-09-17 | 2004-04-01 | Arqule, Inc. | Novel lapacho compounds and methods of use thereof |
| AR042052A1 (es) * | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| WO2006087919A1 (ja) * | 2005-01-28 | 2006-08-24 | Takeda Pharmaceutical Company Limited | 難水溶性物質含有微細化組成物 |
| JP2006290871A (ja) * | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法 |
| TW200803854A (en) * | 2005-09-30 | 2008-01-16 | Smithkline Beecham Corp | Pharmaceutical compositions |
| EP1860126A1 (en) * | 2006-05-26 | 2007-11-28 | INEOS Manufacturing Belgium NV | Polyolefin powder |
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| KR20110031370A (ko) * | 2008-07-08 | 2011-03-25 | 베타 파마, 인크. | 염산 ｉｃｏｔｉｎｉｂ, 합성, 결정형, 약학적 조성물 및 이의 사용 |
| NZ602328A (en) * | 2010-03-19 | 2014-11-28 | Boston Biomedical Inc | Novel compounds and compositions for targeting cancer stem cells |
| DK2547205T3 (da) * | 2010-03-19 | 2024-05-27 | 1Globe Biomedical Co Ltd | Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller |
| CN104016951B (zh) * | 2010-03-19 | 2016-07-13 | 北京强新生物科技有限公司 | 靶向癌症干细胞的化合物和组合物 |
-
2011
- 2011-03-21 CN CN201410101861.9A patent/CN104016951B/zh active Active
- 2011-03-21 ES ES16182813.2T patent/ES2689928T3/es active Active
- 2011-03-21 RU RU2016123004A patent/RU2657750C1/ru active
- 2011-03-21 SG SG10201502079VA patent/SG10201502079VA/en unknown
- 2011-03-21 SG SG10201704745UA patent/SG10201704745UA/en unknown
- 2011-03-21 DK DK16182813.2T patent/DK3108750T3/en active
- 2011-03-21 CN CN201710134235.3A patent/CN106860443A/zh active Pending
- 2011-03-21 RU RU2015142279A patent/RU2015142279A/ru not_active Application Discontinuation
- 2011-03-21 CN CN201710613672.3A patent/CN107311969B/zh active Active
- 2011-03-21 CA CA2993363A patent/CA2993363A1/en not_active Abandoned
- 2011-03-21 EP EP17196754.0A patent/EP3295796A1/en active Pending
- 2011-03-21 EP EP16182813.2A patent/EP3108750B1/en active Active
- 2011-03-21 NZ NZ701237A patent/NZ701237A/en not_active IP Right Cessation
- 2011-03-21 SG SG10201706265PA patent/SG10201706265PA/en unknown
- 2011-03-21 CA CA2959951A patent/CA2959951A1/en not_active Abandoned
- 2011-03-21 NZ NZ712826A patent/NZ712826A/en unknown
- 2011-03-21 HU HUE11757135A patent/HUE066482T2/hu unknown
- 2011-03-21 CA CA2959931A patent/CA2959931A1/en not_active Abandoned
- 2011-03-21 PT PT117571356T patent/PT2547205T/pt unknown
-
2014
- 2014-03-03 JP JP2014040225A patent/JP5993390B2/ja not_active Expired - Fee Related
- 2014-03-03 JP JP2014040227A patent/JP2014098050A/ja not_active Withdrawn
- 2014-03-03 JP JP2014040226A patent/JP2014098049A/ja not_active Withdrawn
-
2015
- 2015-02-25 JP JP2015035285A patent/JP2015098489A/ja active Pending
- 2015-09-11 JP JP2015179115A patent/JP6246169B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-30 JP JP2016194176A patent/JP2016222723A/ja not_active Withdrawn
-
2017
- 2017-10-13 JP JP2017199380A patent/JP2018002744A/ja not_active Withdrawn
-
2018
- 2018-04-20 JP JP2018081329A patent/JP2018115209A/ja not_active Withdrawn
-
2020
- 2020-01-31 JP JP2020014705A patent/JP2020063308A/ja not_active Withdrawn
- 2020-05-08 JP JP2020082479A patent/JP2020114888A/ja active Pending
-
2021
- 2021-12-06 JP JP2021197732A patent/JP2022020002A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2745471T3 (es) | Formulaciones orales de liberación inmediata para quinazolinonas sustituidas | |
| JP2014098048A5 (enExample) | ||
| CN103096895B (zh) | 烟酸模拟物及其使用的方法 | |
| RU2012144421A (ru) | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки | |
| IL258732A (en) | Salts and their benzene and polymorphs | |
| JP2019011369A (ja) | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン | |
| KR20170087926A (ko) | 지방산 시스테아민 콘주게이트 및 자가포식의 활성제로서 이의 용도 | |
| JP2015503593A5 (enExample) | ||
| RU2012144420A (ru) | Новые способы направленного воздействия на раковые стволовые клетки | |
| EP3528803A1 (en) | Compounds and methods to sensitize cancer cells to cisplatin | |
| JP5993390B2 (ja) | がん幹細胞を標的とするための新規の化合物および組成物 | |
| EA028452B1 (ru) | Лечение рака молочной железы | |
| ES2948444T3 (es) | Composiciones que comprenden 15-HEPE | |
| JP2016516772A (ja) | オキサシクロヘプタン及びオキサビシクロヘプテンの配合物 | |
| JP7197370B2 (ja) | がんの予防および／または治療のための化合物、組成物および方法 | |
| JP2013529645A (ja) | ナイアシン模倣体、およびその使用方法 | |
| AU2019351035A1 (en) | Compound and use thereof | |
| EP3458448A1 (en) | Methods of using fasn inhibitors | |
| RU2015140611A (ru) | Коньюгат бензофуранона и индола или азаиндола, его получение и применения | |
| WO2019084300A1 (en) | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | |
| CN113893240A (zh) | 包含15-hepe的组合物和其使用方法 | |
| MX2011011526A (es) | Formulacion lipida de promotor de apoptosis. | |
| JP2016514706A5 (enExample) | ||
| RU2014125519A (ru) | Ацил-гидразоновые и оксадиазоловые соединения, фармацевтические композиции, содержащие их, и их применение | |
| IL300405A (en) | Methods for treating respiratory diseases characterized by excessive secretion of mucus |